← Product Code [LKJ](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ) · K024223 # LIQUICHEK ANTI-RNP CONTROL, POSITIVE, CATALOG #116 (K024223) _Bio-Rad · LKJ · Jan 13, 2003 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ/K024223 ## Device Facts - **Applicant:** Bio-Rad - **Product Code:** [LKJ](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ.md) - **Decision Date:** Jan 13, 2003 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5100 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Indications for Use The Liquichek™ Anti-RNP Control, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of ribonucleoprotein (RNP) autoantibodies. ## Device Story Liquichek™ Anti-RNP Control, Positive is a liquid, human serum-based quality control material containing preservatives. It is designed for use in clinical laboratories to monitor the performance of indirect immunofluorescent assays for RNP autoantibodies. The device is unassayed, meaning it does not have a pre-determined target value; laboratory personnel use it to verify the consistency and accuracy of their testing procedures over time. By comparing results obtained from the control against expected performance ranges, clinicians can ensure the reliability of patient test results. The control is stable for 60 days once opened and 2 years when stored unopened at 2-8°C. ## Clinical Evidence No clinical data. Stability studies were performed to validate shelf life (2 years at 2-8°C) and open-vial stability (60 days at 2-8°C). ## Technological Characteristics Human serum matrix with added preservatives. Liquid form. Unassayed. Storage at 2°C to 8°C. No software or electronic components. ## Regulatory Identification An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues). ## Predicate Devices - Liquichek™ Anti-RNP Control, EIA ([K984476](/device/K984476.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 1024233 ### Summary of Safety and Effectiveness Liquichek™ Anti-RNP Control, Positive #### 1.0 Submitter Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 Telephone: (949) 598-1200 (949) 598-1555 Fax: ### Contact Person Yvette Lloyd Senior Regulatory Affairs Specialist Telephone: (949) 598-1465 ### Date of Summary Preparation December 20, 2002 #### 2.0 Device Identification | Product Trade Name: | Liquichek™ Anti-RNP Control, Positive | |---------------------|----------------------------------------| | Common Name: | Anti-RNP Antibody, Antigen and Control | | Classifications: | Class II | | Product Code: | 82LKO | | Regulation Number: | 21 CFR 866.5100 | #### 3.0 Device to Which Substantial Equivalence is Claimed Liquichek™ Anti-RNP Control, EIA Bio-Rad Laboratories 510 (k) Number: K984476 #### 4.0 Description of Device This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience. JAN 1 3 2003 {1}------------------------------------------------ #### 5.0 Statement of Intended Use The Liquichek™ Anti-RNP Control, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of ribonucleoprotein (RNP) autoantibodies. #### Comparison of the new device with the Predicate Device 6.0 This control is substantially equivalent to the following quality control material for autoimmune analysis that is currently in the market: Liquichek™ Anti-RNP Control, EIA Bio-Rad Laboratories 510 (k) Number: K984476 Table 1. Similarities and Differences between new and predicate device. | Characteristics | Liquichek™ Anti-RNP Control, Positive
(New Device) | Liquichek™ Anti-RNP Control, EIA
(Predicate Device) | |-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Similarities | | | | Matrix | Human Serum | Human Serum | | Storage
(Unopened) | 2°C to 8°C
until expiration date | 2°C to 8°C
until expiration date | | Form | Liquid | Liquid | | Analyte | Anti-RNP | Anti-RNP | | Value Assignment | Unassayed | Unassayed | | Differences | | | | Intended Use | The Liquichek™ Anti-RNP Control, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of ribonucleoprotein (RNP) autoantibodies. | The Liquichek™ Anti-RNP Control, EIA is intended for use as an unassayed quality control to monitor enzyme immunoassay procedures for the detection of ribonucleoprotein (RNP) autoantibodies. | | Stability
(Opened) | Once opened the analyte will be stable for 60 days. | Once opened the analyte will be stable for 30 days. | {2}------------------------------------------------ #### Summary of Performance Data 7.0 Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ Anti-RNP Control, Positive. Product claims are as follows: - 7.1 Once the control is opened the analyte will be stable for 60 days when stored tightly capped at 2 to 8°C. - 7.2 The control is stable for 2 years when stored unopened at 2 8°C. Real time studies will be ongoing to support the shelf life of this product. All supporting data is retained on file at Bio-Rad Laboratories. {3}------------------------------------------------ ### DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines representing hair or clothing. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 ## JAN 1 3 2003 Ms. Yvette Lloyd Senior Regulatory Affairs Specialist Bio-Rad Laboratories. OSD 9500 Jeronimo Road Irvine, CA 92618-2017 Re: k024223 Trade/Device Name: LiquichekTM Anti-RNP Control, Positive Regulation Number: 21 CFR 866.5100 Regulation Name: Antinuclear antibody immunological test system Regulatory Class: Class II Product Code: LKJ Dated: December 20, 2002 Received: December 23, 2002 Dear Ms. Lloyd: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21. Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {4}------------------------------------------------ ### Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours, Steven Autman Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ Page 1 of 1 510 (k) Number (if known):____________________________________________________________________________________________________________________________________________________ Device Name: Liquichek™ Anti-RNP Control, Positive Indications for Use: Liquichek Anti-RNP Control, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of ribonucleoprotein (RNP) autoantibodies. (PLEASE DO NOT WRITE BELOW THE LINE-CONINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription use_ or Over-the Counter use YP Reeves for J. Bautista (Division Sign-Off) Division of Clinical Laboratory I 510(k) Number - --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ/K024223](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ/K024223) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com